Pyxis Oncology files Apexigen audited FY22 results; net loss $32M, cash $14.8M

Pyxis Oncology, Inc.

Apexigen FY22 net loss of $32.1M, revenue $0; R&D expense $23.0M, G&A $9.7M.
Audited balance sheet at Dec 31, 2022: cash and short-term investments $16.8M, accumulated deficit $176.8M.
Auditors included going-concern doubt; Apexigen had suffered recurring losses and net capital deficiency.
The amendment provides pro forma combined financials as of June 30, 2023 and for FY22, giving effect to the August 23, 2023 acquisition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.